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Abstract
Genome editing technology has evolved rather quickly and become accessible to most researchers. It has resulted in
far reaching implications and a number of novel designer systems including epigenome editing. Epigenome editing
utilizes a combination of nuclease-null genome editing systems and effector domains to modulate gene expression.
In particular, Zinc Finger, Transcription-Activator-Like Effector, and CRISPR/Cas9 have emerged as modular systems
that can be modified to allow for precision manipulation of epigenetic marks without altering underlying DNA
sequence. This review contains a comprehensive catalog of effector domains that can be used with components of
genome editing systems to achieve epigenome editing. Ultimately, the evidence-based design of epigenome editing
offers a novel improvement to the limited attenuation strategies. There is much potential for editing and/or correcting
gene expression in somatic cells toward a new era of functional genomics and personalized medicine.
Keywords: Regulation of gene expression, Functional genomics, Stem cells, dCas9, CRISPR/Cas9, Zinc Finger,
Transcription-Activator-Like Effector (TALE), Synthetic biology
Background
The modulation of gene expression can be achieved by
a variety of biotechnologies such as RNA interference,
non-precision drugs, and artificial transcription factors
(ATFs). Epigenome editing is an emerging field of synthetic biology that falls under the category of ATF [1]. It
is distinguished from other gene expression modulation
technologies in that it can create precise and long-lasting epigenetic modification without the need to keep or
maintain the system after the initial event [2].
The epigenome editing systems that are the focus of
this review contain the DNA-binding element of genome
editing systems. Thus, in order to gain a full appreciation
for epigenome editing one must start with the fundamentals of genome editing as the two share not only components but also obstacles. Genome editing represents
a revolution in genetic engineering as it allows for precision targeting and manipulation of genome. Genome
*Correspondence: blaufer@uwo.ca
Molecular Genetics Unit, Department of Biology, University of Western
Ontario, London, ON, Canada

editing systems rely on two components, a DNA-binding element, and nuclease, to modify the targeted DNA
sequence. Genome editing can be used to study protein
function by altering coding sequence or achieve transcriptional control by altering the sequence of regulatory regions. Epigenome editing, on the other hand, uses
the same DNA-binding principle but utilizes an effector
domain, rather than a nuclease. The effector domain is a
fragment of a desired regulatory protein and is used to
create a desired epigenetic mark at a targeted locus without altering the underlying sequence.
DNA‑binding genome editing systems

The concept of genome editing is not new. What is new
is the refinement of methods that make it feasible for
most laboratories to undertake the protocol successfully. Today, genome editing allows for precise manipulation of DNA sequences and brings about desired genetic
changes at will in vitro and in vivo [3–5]. The principle
involves precise targeting of a specific DNA sequence
in the genome to create a site-specific double-stranded
break using a nuclease. A cell will then attempt to correct

© 2015 Laufer and Singh. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Laufer and Singh Epigenetics & Chromatin (2015) 8:34

this damage by homology-directed repair (HDR), which
makes it possible to introduce desired donor sequence(s).
Additionally, non-homologous end-joining (NHEJ) can
be used to delete desired sequences. The methods available make use of Zinc Fingers (ZFs), TranscriptionActivator-Like Effectors (TALEs), and the Clustered
Regulatory Interspaced Short Palindromic Repeats
(CRISPR) sequences with CRISPR-Associated Protein 9
(Cas9) detailed below.
ZFN

Zinc Finger Nuclease (ZFN) is the oldest genome editing technology [6–8]. It is based on two-modules. The
first are Zinc Finger Proteins that recognize and bind to
DNA sequences. Zinc finger proteins coordinate zinc
ions using a backbone of conjugated Cysteine (Cys) and
Histidine (His) residues to achieve their structure. They
come in a number of folding groups the most widely used
being the Cys2His2 group. This folding group represents
the classical zinc finger and is widely used as a natural
transcription factor in mammals. Cys2His2 ZFs also have
a relatively conserved backbone. ZF specificity for DNA
sequence comes from a part of the α helix, known as the
recognition domain, which binds to the major groove of
DNA. The specificity is determined by amino acids in
the recognition domain. Variation in this region, either
naturally occurring or synthetic, results in recognition
of alternative nucleic acid sequences. Experimentally, a
designer zinc finger is fused to a nuclease (FokI), which
requires dimerization for double-stranded DNA cleavage. Here, the targeting specificity comes about from the
recognition domain, with each ZF recognizing 3–4 bp
per amino acid in the domain. Typically, ZFN systems
use a combination of 3–6 ZFs fused to a FokI domain.
The inverted dimer required for nuclease activity gives
additional sequence specificity as there is a required
space, known as the spacer. This design approach facilitates a target specificity of ~24 bp, which is enough to
target most unique regions in most genomes (Fig. 1a).
In terms of practicality, ZFNs are limited by the higher
cost and effort of designing the custom proteins, interactions between residues affecting targeting, and altered
sequence recognition from the effects of additional
genomic and chromatin content surrounding the target
sites [9]. However, they have the advantage of being oldest, most studied, and only genome editing system to be
in clinical trials.
TALEN

TALENs represent a fusion of a Transcription-ActivatorLike Effector (TALE), which is a viral element evolved to
target plant transcription and a designer nuclease [10–
12]. TALEs have a central repeat domain that confers
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its sequence specificity (Fig. 1b). This domain is 33–35
amino acids long and has two highly variable sites at
the 12th and 13th amino acids, which are known as the
repeat variable di-residues (RVDs). Different combinations at the RVDs allow for recognition of a single base.
While both ZFN and TALEN systems theoretically allow
for single-base targeted design, TALEs recognize single
nucleotides as opposed to the triplet combinations of a
ZFPs recognition sequence. Also, this system performs
better than ZFNs since they are not as influenced by
sequence and chromatin surrounding the target site [13–
17]. More importantly, TALEs and TALENs represent a
significant improvement in specificity and protocol [18,
19].
TALENs have been successfully used in mice for mitochondrial transfer, which allows for a 3-parent child. This
is done in order to prevent an inherited disorder in the
mitochondrial genome that would normally be transmitted from the mother. It has recently been approved as a
medical procedure in the UK and is currently under serious consideration in USA. Intriguingly, a mitoTALEN
system was recently used in mice to overcome mitochondria heteroplasmy by targeting and selectively destroying
diseased mitochondria but still allowing for the transmission of wild-type mitochondria in mouse oocytes from
the original mother [20].
CRISPR/Cas9

This system also consists of two components. First, the
Cas9 protein is a nuclease. Second, the CRISPR/Cas9 system consists of a synthetic guide RNA (sgRNA) [21]. The
sgRNA is used for sequence specificity and has a 20 bp
target recognition domain. However, the sgRNA contains
more information than just targeting specificity and has a
complex stem loop structure. The loading of the sgRNA
is critical for activating the catalytic activity of Cas9 [22].
The binding and catalytic activity of the Cas9/sgRNA
complex on target DNA is also dependent on the presence of an external sequence known as the Protospacer
Adjacent Motif (PAM) [23]. Target DNA sequences
complementary to the sgRNA are ignored by the Cas9/
sgRNA complex if PAM is not present upstream of the
target DNA. This is because DNA strand separation and
the RNA–DNA heteroduplex are initiated at the PAM
site (Fig. 1c). While there are target sequence limitations
created by the requirement of PAM before the target
sequence, research into overcoming the initial limitations
is showing that by using Cas9 orthologs with alternative
PAM sequences [24–26] and distinct sgRNA recognition
sequences [27] there may be no practical limit to the targetable sites in the genome. Another practical advantage of
CRISPR/Cas9 is the relative ease of creating short custom
nucleotide (<100 bp) sequences compared to engineering
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Fig. 1 (Epi)Genome editing systems. a Zinc Finger Nuclease (ZFN), b Transcription-Activator-Like Effector Nuclease (TALEN), c CRISPR/Cas9, d Zinc
Finger (ZF) with a DNA methyltransferase effector domain, e Transcription-Activator-Like Effector (TALE) with a histone methyltransferase, and f
Catalytically deactivated Cas9 (dCas9) and sgRNA from with a histone acetyltransferase. Components are not to scale as critical features are exaggerated and some non-variable features are removed

proteins to bind different sequences while also maintaining activity and specificity. The CRISPR/Cas9 protocol
[28–32] has undergone numerous improvements, allowing it to become the most widely used genome editing
system. The advantage of CRISPR/Cas9 over ZFNs and/
or TALENs is its scalability in that multiple sites within
the mammalian genome can be modified simultaneously,
providing a robust, high-throughput approach for gene
editing in mammals. These advantages in this system are
largely due to the fact that RNA, instead of designed protein, is used to specify the target.
The CRISPR system has been adapted to target doublestrand breaks and modify DNA sequence in the genomes
of a number of organisms including humans [33], mice
[34], and zebrafish [35]. In fact CRISPR/Cas9 has been
adopted to work in species ranging from prokaryote to
eukaryote, plant to animal, and vertebrate to invertebrate.
Of particular interest is the fact that in its earliest stages

of development CRISPR/Cas9 has been used to alter the
mouse by using a knockin system [36, 37] and also enabled reverse genetic studies in post-mitotic neurons of
the adult brain [38]. CRISPR/Cas9 has also been used
to generate one-cell embryos that go on to develop into
edited monkeys [39]. Finally, it has been demonstrated
to deplete synaptic proteins in rat hippocampal neuron
cultures [40] and correct the mutation in the hemoglobin
beta gene responsible for sickle cell anemia [41]. This was
done in blood cells derived from induced pluripotent
stem cells (iPSCs) of patients and with a higher efficiency
than possible using ZFNs and TALENs [41, 42].
The CRISPR/Cas9 system can also be used to create
gene drives [43]. Gene drives are a synthetic biological
system in which a transgene can aggressively propagate
independently of natural selection. It can quickly take
over a population in a few generations with only just a
few founders. This is because the mutation edited into

Laufer and Singh Epigenetics & Chromatin (2015) 8:34

Page 4 of 12

a founder will overwrite the content of the wild-type
parent in their offspring, thus it overcomes the diploid genome and makes an inherited heterozygote and
homozygote [44].

immediately upon inducing repression of the system
masking the homozygous mutation. Thus, the CRISPR/
Cas9 technology was able to illustrate a fundamental difference between humans and mice.

Genome editing the epigenome

Epigenome editing

Genome editing systems can also be used to edit the
epigenome in a fashion that is distinct from epigenome
editing, as it involves altering sequence critical to the epigenome. CRISPR/Cas9 has been utilized to study chromatin architecture and make targeted and unprecedented
alterations to the repeat rich regulatory elements. It created deletions, inversions, and duplications that enabled
the study of the clustered protocadherins [45], a complex
locus that generates individual neuronal identity and
is involved in neurodevelopmental disorders [46]. The
approach has lead to the discovery of regulatory elements
from the protocadherin α cluster that are also involved
in the regulation of the γ cluster. Finally, CRISPR/Cas9
has been used to remove CTCF binding sites in the Hox
gene clusters during embryonic stem cell differentiation
in cervical motor neurons and disrupt the topological
chromatin boundaries, turning repressed chromatin into
active chromatin by preventing CTCFs targeted function as a genomic insulator [47]. Also, TALENs have been
used to study long-range chromatin interactions by altering the sequence of inter- and intra-chromosomal contact points [48].
Furthermore, the cross-species capability of CRISPR/
Cas9 has lead to profound insight in mammalian systems that were previously inaccessible at the level of
basic research, particularly in monkeys [49] and humans.
CRISPR/Cas9 has already been used to investigate DNA
methylation machinery. Two genome editing approaches
were developed in an in vivo mouse model, one had a
single gene approach to target the reader MeCP2 that
allowed for visualization and cell sorting and the other
had a multi-gene approach to target the DNA methyltransferases (DNMTs) Dnmt1, Dnmt3a, and Dnmt3b
[38]. More recently, the CRISPR/Cas9 system was used
for experimentation in human embryonic stem cells to
create precise knockout deletions in the DNMTs [50].
By creating catalytically inactivating mutations using
both multiplex and singleplex approaches the targets of
DNMT1, DNMT3A, and DNMT3B were mapped with
single-base pair resolution via whole-genome sodium
bisulfite sequencing. This study was done in reference
to a previous mouse model study of embryonic stem
cells [51]. In both humans and mice, ESCs are viable
without DNMT3A or DNMT3B, but interestingly only
human cells undergo rapid cell death from the removal of
DNMT1. This occurred even with an inducible system to
control the temporal disruption, where cell death occurs

Besides editing genome sequence, genome editing systems have been used in altering the transcription of specific gene(s) without altering the underlying sequence.
This modification for transcriptional alterations involves
exclusion or inactivation of nuclease activity followed
by use of the targeting system fused to a modular effector domain and is known as epigenome editing. A list of
effectors and their effects on gene expression (increase or
decrease) is summarized in Table 1. However, it should
be noted that the effect of epigenetic marks is context
dependent and thus the context of this table is the average consequence of depositing these marks in a promoter
or enhancer. These systems have been used to target integrated/synthetic as well as endogenous loci, a distinction
that is reviewed by de Groote et al. [1].
The function of ATF was the primary purpose for
DNA sequence specificity of designer ZFs and TALEs
with the goal of precise transcriptional activation,
also known as transactivation. Transactivation effector domains are based on viral elements. The original VP16 domain [52] comes from Herpes Simplex
Viral Protein 16 and consists of amino acids 437–447
[DALDDFDLDML]. VP16 was later engineered into
VP64 domain [53], which is a fusion containing four
tandem copies of VP16 connected by glycine-serine
linkers [DALDDFDLDML]-GS-[DALDDFDLDML]-GS[DALDDFDLDML]-GS-[DALDDFDLDML]. It is the
most widely used transactivation domain. Interestingly,
one effect of using the VP64 transactivation domain is
that it recruits p300, which causes activating H3K27Ac
to increase at the targeted locus over time and represents an example of transcription driving transcription
[54]. Transcriptional repression, on the other hand, utilizes repression domains [55, 56] and is typically achieved
by variants of a 45-aa segment from Krüppel-associated
boxes (KRAB) [55] or repressive epigenomic modifications [57, 58]. The KRAB repressor domain appears to be
the most potent natural repressor in the genome and used
by half of zinc fingers, which make up half of the genome’s
transcription factors. Interestingly, the KRAB repressor
domain recruits histone modifying domains and results in
a decrease of activating H3K4me3 and increase of repressive H3K9me3 and H3K27me2 but does not alter DNA
methylation [59]. However, these modifications may not
reflect the immediate effect of transcriptional repression
and could be a later consequence [60]. A bacterial DNA
methyltransferase (M.SssI) is also capable of repression
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Table 1 A comprehensive selection of effector domains for epigenome editing systems
Effect

Domain

Consequence

Reference(s)

Activation

VP64
VP16
p65
SAM
VPR

Activates transcription by recruiting a transcription complex and can
then recruit histone acetylation as a consequence of the induced
transcription. Can recruit p300 to deposit H3K27ac

Seipel et al. [52]
Beerli et al. [53]
Konermann et al. [57, 84]
Gilbert et al. [81, 87]
Mali et al. [83]
Perez-Pinera et al. [30]
Kearns et al. [85]
Hu et al. [95]
Tanenbaum et al. [96]
Gao et al. [54]
Chakraborty et al. [90]
Heller et al. [125]
Zalatan et al. [88]
Nihongaki et al. [102]
Polstein and Gersbach [103]
Chavez et al. [97]

Repression

KRAB
SID
Tbx3-RD

Represses transcription by preventing transcription complex formation.
May also recruit other repressive modifications

Margolin et al. [55]
Ayer et al. [56]
Cong et al. [17]
Gilbert et al. [81, 87]
Chen et al. [105]
Kearns et al. [85]
Hu et al. [95]
Ma et al. [59]
Gao et al. [54]
Zalatan et al. [88]
Telese et al. [89]

DNA methylation

DNMT3A DNMT3B
M.EcoHK31I
M.HhaI
M.SssI
DNMT3A-3L

Represses transcription

Li et al. [63]
Meister et al. [64]
Chaikind et al. [66, 69]
Rivenbark et al. [65]
Siddique et al. [67]
Nunna et al. [68]
Stolzenburg et al. [70]
Kungulovski et al. [71]
Bernstein et al. [76]

DNA demethylation

TDG
TET1
TET2

Activates transcription

Gregory et al. [72]
Maeder et al. [73]
Chen et al. [78]

H3K9me

G9a (EHMT)
Suvar
KYP
GLP

Represses transcription

Snowden et al. [61]
Falahi et al. [62]
Konermann et al. [57]
Heller et al. [125]
Kungulovski et al. [71]
Cho et al. [74]

H3K9 demethylation

JMJD2B

Activates transcription

Hu et al. [95]

H3K9 deacetylation

Sin3a

Represses transcription

Konermann et al. [57]

H3K4me2 demethylation LSD1

Also leads to H3K27ac removal; both repress transcription.
Ideal for enhancers

Mendenhall et al. [75]
Kearns et al. [58]

H3K27me3

NUE

Represses transcription

Konermann et al. [57]

H3K27 demethylation

JMJD3

Activates transcription

Hu et al. [95]

H3K27ac

p300

Activates transcription. Ideal for enhancers

Hu et al. [95]
Hilton et al. [91]

H4K8 deacetylation

HDAC8
RPD3
Sir2a

Represses transcription

Konermann et al. [57]

H4K20me3

tgSET8

Represses transcription

Konermann et al. [57]

Affinity enrichment

PrA
FLAG

Locus-specific chromatin enrichment for protein analysis

Byrum et al. [109, 113]
Fujita et al. [110, 111]
Waldrip et al. [112]
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Table 1 continued
Effect

Domain

Consequence

Reference(s)

Cell imaging

GFP
Cherry
BFP

Sub-nuclear visualization

Chen et al. [46]
Anton et al. [106]
Ma et al. [108]

and recruiting a heterochromatin protein, H3K9me3, and
H3K27me2 [59]. The following are examples of how some
of these effector domains have been used with DNAbinding platforms to modulate gene expression.
Zinc Fingers

The ZF system has been extensively used as an artificial
transcription factor (Fig. 1d). It was first used to establish epigenome editing in 2002 when an engineered ZF
fused to a histone methyltransferase was able to show
that H3K9 methylation is causative in gene repression
[61]. Since then ZFs have been designed with histone
methyltransferases to repress oncogenes [62]. ZFs have
also been utilized with DNA methylation machinery. In
these cases, the DNA methyltransferases (DNMTs) were
fused to designer ZFs to cause targeted DNA methylation and repress related gene expression [63–70]. Such
designs have varied from engineered bacterial methyltransferases to select domains of the mammalian
DNMT family. Recently, a ZF fused to DNMT3A or the
H3K9 methylation writer GLP were delivered by adenoviral delivery system to control the regulation of a cancer gene by targeting its promoter [71]. While DNA
methylation repressed longer than H3K9 methylation,
the effect was not long-lasting and the authors speculate that multivalent epigenetic modifications must be
designed for long-term effects when epigenome editing
and to accommodate for large-scale chromatin domains.
One promising design of effector domain involves a
fusion of the catalytic domain of the de novo methyltransferase DNMT3A and C-terminal domain of (the
catalytically inactive) DNMT3L, which naturally stimulates DNMT3A’s activity [67]. Alternatively, ZFs can be
used to enhance gene expression by being fused with the
DNA demethylase thymidine DNA glycosylase (TDG)
[72]. However, epigenetic editing by ZFs is prone to the
same problems as genome editing, genome wide off-target effects caused by the nature of ZF recognition being
altered by additional (epi)genomic context [60].
TALEs

Taking the modular approach of ZFs, TALEs have been
modified to induce transcriptional activation [73] and
repression [74] (Fig. 1e). TALE epigenome editing systems have been used to target and modify chromatin at enhancers [75] and regulate gene expression via

DNA methylation [76]. Furthermore, using a combination of epigenome editing systems and optogenetics
for light induction, it was shown that gene expression,
histone acetylation (H3K9ac) and histone methylation
(H3K27me3) in the mouse brain can be targeted and
modulated in a reversible fashion [57] at will. TALEs have
also been efficiently fused to the TET family of active
DNA demethylases and drive gene expression in targeted
sequences by actively removing DNA methylation [77,
78]. The fusion of the DNMT3A and DNMT3L was replicated in TALEs [76].
dCas9

The CRISPR/Cas9 system has also been used to alter transcription [79–88]. This has been achieved by targeting
with sgRNAs and a catalytically inactivated Cas9 (dCas9),
which creates a RNA-based targeting system that can be
fused to effector domains. Therefore, dCas9 based epigenetic editing gains the target specificity of CRISPR/Cas9
without causing a double-stranded break and while carrying out the function of the effector domain at the target
site (Fig. 1f ). A dCas9 system fused to the KRAB transcription repressing domain has been used to confirm the
function of LRP8-Reelin-regulated neuronal enhancers
in cortical neurons and lead to the discovery of a novel
synapse-to-nucleus pathway related to glutamatergic
signaling [89]. However, in the context of transcriptional
control the dCas9 system often achieves low effectiveness, which can be improved by the tiling of multiple
sgRNAs. Yet another approach to transcription activation
via dCas9 has been to fuse two activation domains per
dCas9. This system was used to reprogram the cell lineage of stem cells and drive subsequent phenotypes [90].
Also, the histone acetyltransferase p300 can be used as an
effector domain to achieve H3K27 acetylation and induce
gene expression by targeting the mammalian β-globin
locus control region, which is something that could not
be achieved by a VP64 domain [91].
Since each system has its own strengths and weaknesses when it comes to off-target and on-target effects,
price, cellular toxicity, and ease of use, a standardized
comparison system is needed [92, 93]. In practice, each
system may show a unique potential when used on
their own or coupled together [94]. This has recently
been exemplified in the case of transcriptional activation of pluripotency factors in humans and mice by both
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CRISPR- and TALE-based editing systems [95]. When
comparing the ability to drive gene expression by targeting enhancers, it was found that TALEs could outperform CRISPR/Cas9 and the authors recommended an
approach combining both systems for highly efficient
transcriptional regulation [54]. However, this comparison
used initial and less effective CRISPR activators and not
the most enhanced genetically engineered improvements
[84, 87] that are described below.
Engineered improvements

Several laboratories have begun to utilize the genetically engineered Cas9 proteins and sgRNAs (Fig. 2).
One alterative involves a versatile scaffolding platform
to attach multiple VP64 domains to dCas9 [96] and a
different approach uses the tripartite activator VP64p65-Rta (VPR) [97]. Another variation is the use of second-generation sgRNAs (sgRNA 2.0) for multi-effector
programming [88], where scRNAs (extended sgRNAs)
have effector domain recruitment sites added into their
sequence after the targeting site. This approach further
creates modularity in that there are layers of variation
created in Cas9 orthologs having different sgRNA recognition sites. Additional layers are then created by the fact
that each sgRNA can be programmed to have two recognizable loops that can be bound in homogenous or heterogeneous configurations by a unique binding protein
being fused to unique effector domains [88]. One example of this system is the Synergistic Activation Mediator (SAM), which is a potent transcription activation
system [84]. In SAM, the exposed and engineered RNA
loops from the Cas9–sgRNA–DNA complex are used as
anchoring points for the RNA-binding protein (MS2) that
is also fused to a p65-HSF1 fusion effector domain. This
allows for a synergistic combination in activating gene
expression at levels much higher than a single effector
domain. Another approach involves further enhancing
the sgRNA to create a system known as CRISPR-Display
[98]. CRISPR-Display allows for functional RNA domains
(~4.8 kb) to be inserted into the sgRNA loops at multiple positions, including the same loop as sgRNA 2.0 as
well as 5′ and 3′ positions. This approach uses functional
motifs like the protein-binding cassettes of earlier sgRNA
2.0 approaches but also enables long non-coding RNA to
be inserted into the dCas9/sgRNA complex. Ultimately,
the CRISPR-Display system enables precision ectopic
targeting of RNA and ribonucleoprotein to loci of interest in order to fully characterize the functionality of the
RNA.
Combinatorial biotechnology

(Epi)genome editing systems allow not only for fusing a
genome editing system to an effector but they can also
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add additional genetic changes and facilitating methodologies. For example, Konermann et al. [57] used transcriptional control or histone modifying (acetylation
and methylation) effector domains (Table 1) along with
a light inducible (optogenetic) element. The optogenetic
induction system involves light-sensitive cryptochrome
2 (CRY2) and CIB1, its binding partner [99]. These two
proteins only heterodimerize upon exposure to blue
light, a process that is rapid and reversible, and can be
applied to study neurons in mammalian brains [100, 101].
They can then be separately fused to an epigenome editing system, with one attached to the targeting system
and the other to the effector. This can be utilized in epigenome editing by allowing for the editing to be induced
when and where it is desired in a rapid and reversible
manner. The optogenetic approach has also been combined with CRISPR/Cas9 transactivation systems [102,
103]. Alternate inducible transactivation systems use
steroids that has been created using TALEs [104]. Finally,
cell imaging can also be achieved using an EGFP effector
domain [105] that can visualize pericentric, centric, and
telomeric repeats [106]. This allows for the visualization
of repetitive sequences using a single sgRNA or an array
of sgRNAs for non-repetitive sequences to enable visualization and tracking through cellular processes. This technique was demonstrated by imaging telomere dynamics
and the dynamic sub-nuclear localization of a single gene
through mitosis. Another visualization system has been
developed that allows for multicolor analysis. It was initially successful in TALEs [107] and was recently adopted
for dCas9 orthologs with three spectral systems [108].
The spectral systems were used to target telomeres, several target loci, and also determine the intranuclear distance between loci on different chromosomes, which
allowed for the assessment of DNA compaction in live
cells.
Furthermore, epigenome editing systems have been
used for enrichment and purification of proteins interacting with target loci. They have the potential to allow
for an examination of all the proteins and histone PTMs
associated with a single genomic locus, the epiproteome
[109]. These techniques couple chromatin immunoprecipitation and the target specificity of genome editing
systems (without the catalytic activity) by using an effector domain to allow for enrichment that can then be
coupled to analysis by mass spectrometry. One variant
of this approach is known as engineered DNA-binding
molecule-mediated chromatin immunoprecipitation
(enChIP). It has been developed using TALEs [110] and
CRISPR/Cas9 [111] to study telomeres. Another variant involving the CRISPR/Cas9 system has also been
developed and termed Chromatin Affinity Purification
with Mass Spectrometry (CRISPR-ChAP-MS) [112].
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Fig. 2 Designer epigenome editing systems based on dCas9. VPR refers to the effector domain, which is a tripartite design. sgRNA 2.0 refers to a
scaffolding system that allows for modular effectors to be added to the sgRNAs that have been modified to contain protein-binding sites for RNA
recognizing proteins. SAM refers to a synergistic activator that contains an effector domain fused to the dCas9 protein as well as the sgRNA 2.0
design to add additional designer activators. Components are not to scale as critical features are exaggerated and some non-variable features are
removed

This approach was able to reveal the changes during
the activation of transcription although it had difficulty
with repressive contexts, including when using TALEs
[113]. The developments identified above represent some
selected issues that will be further enabled using epigenome editing technology. More importantly, we anticipate additional future modifications and applications of
this system to provide insights into other biological problems that have remained difficult to investigate.

Future challenges

A flurry of publications in recent years have established
that (epi)genome editing may hold the key to the next
generation of genomic revolution; the alteration of gene
sequences as well as its expression in designated tissues at
will. To date, most of this research has focused on understanding biological complexities including correction of
gene defects that may be associated with diseases. It is also
apparent that genome editing systems have met a number
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of challenges in providing the needed proof of principle
for epigenome editing systems. These include off-target
effects, editing efficiency, delivery [114–116], and cytotoxicity [117]. In particular given the complexity of the
genome sequence and organization, it may not be easy to
avoid off-target effects in most if not all cases, particularly
in the highly open and dynamic chromatin of embryos
that is not well characterized. These limitations mean that
only some of the cells in question will have the desired outcome. This level of correction and expected somatic mosaicism may be sufficient in some but not all cases.
It is apparent that most research on genomic correction
in humans will involve ex vivo methods [118]. The ex vivo
approach involves harvesting appropriate cells from the
patient, correcting them in culture, and then returning
the corrected cells via autologous transformation. The
in vivo approach involves directly transforming somatic
cells in the patient. On the other hand, ZFs can cross cell
membranes and induce genome editing in human cells
[119, 120]. Furthermore, incorporating tandem nuclear
localization signal repeats into the ZFN protein backbone
may improve cell permeability to ~13-fold and allow for
genome modification success rates of 26 % in CD4+ T
cells and 17 % in CD34+ hematopoietic progenitor cells
[121]. TALENs can also be modified for enhanced cell
penetrating abilities by conjugating with peptides that
allow for optimized protein machinery delivery. It may
allow for effective parallel viral transfection [122]. Cas9
and sgRNAs have also been utilized for effective genome
editing that does not require transformation of the editing system into host by using common cationic lipid
nucleic acid transfection reagents to deliver the system
[123] or by using electroporation [124]. As it stands,
there are still key obstacles to overcome with epigenome
editing but given the exponential rate of advancement
most technological limitations will shortly be overcome.

Conclusion
It is apparent from the examples listed above that future
application of epigenetic correction using the current
and evolving technologies is only limited by imagination.
Besides monogenic diseases, epigenome editing may
apply in cases of complex traits, such as the long-term
effects on neuroplasticity from stress and drug exposure.
A recent example showed that a locus-specific epigenetic
remodeling may control cocaine addiction- and depression-related behaviors [125]. This study used ZFs and
TALEs to target histone methylation (H3K9me2 via G9a)
or acetylation (correlated with transcriptional activator;
p65) at transcription factor binding sites (SRF and CREB)
of the Fosb promoter in the nucleus accumbens, a brain
region involved in reward and addiction.
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There is every reason to argue that cell-type-specific
epigenome editing systems should be used to modify cells
in vivo and/or in vitro to further basic science as well as
correct a variety of diseases. Ultimately, epigenome editing represents a much-needed tool for the advancement
of functional genomics and personalized medicine. Yet,
until the trans-generational and population level consequences are fully understood and debated it must remain
limited to somatic cells and not cross to the human
germ-line.
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